insights_auto
Varför har ALNOV gått upp 4,65%?
Gå på djupetchevron_right
ALNOV:EPA
Novacyt SA
0,45 €
arrow_upward
+4,65%(+0,020) 1 d
13 nov., 17:35:28 GMT+1 · EUR
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för ALNOV …
Öppen
0,44 €
Högt
0,46 €
Lågt
0,43 €
Börsvärde
30,13 mn
Genomsn. vol.
164,75 tn
Volym
156,80 tn
52v högst
1,04 €
52v lägst
0,29 €
EPS
−0,38 €
Utestående aktier
72,59 mn
Antal anställda
228
Öppen
0,44 €
Högt
0,46 €
Lågt
0,43 €
Börsvärde
30,13 mn
Genomsn. vol.
164,75 tn
Volym
156,80 tn
52v högst
1,04 €
52v lägst
0,29 €
EPS
−0,38 €
Utestående aktier
72,59 mn
Antal anställda
228
Nyheter och artiklar
Från webbkällor och nyhetspartner
BigGo Finance
·
för 4 timmar sedan
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
The Motley Fool
·
för 3 timmar sedan
Tesla Is Down 13% in 2026 While the S&P 500 Is Up. Here’s the 1 Catalyst Left This Year That Could Flip That.
24/7 Wall St.
·
för 2 timmar sedan
Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500
Traders Union
·
för 1 timme sedan
Chris Ciovacco: Semiconductors SMH and S&P 500 SPY show several possible support areas
Profil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Om Novacyt SA
VdDavid Allmond
Anställda228
Grundades3 juli 2006
Huvudkontor-
SektorHealth Care
Bransch-
Webbplatsnovacyt.com